Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study
Hiroshi Mukae, Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Hiroki Sakaguchi, Takuhiro Sonoyama, Genki Ichihashi, Takao Sanaki, Keiko Baba, Yuko Tsuge, Takeki Uehara
doi: https://doi.org/10.1101/2022.06.22.22276792
Hiroshi Mukae
1Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Hiroshi Yotsuyanagi
2The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
Norio Ohmagari
3Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
Yohei Doi
4Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
5Departments of Microbiology and Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Japan
Hiroki Sakaguchi
6Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
Takuhiro Sonoyama
6Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
Genki Ichihashi
6Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
Takao Sanaki
7Pharmaceutical Research Division, Shionogi & Co., Ltd., Toyonaka, Japan
Keiko Baba
7Pharmaceutical Research Division, Shionogi & Co., Ltd., Toyonaka, Japan
Yuko Tsuge
6Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
Takeki Uehara
6Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
Article usage
Posted June 26, 2022.
Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study
Hiroshi Mukae, Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Hiroki Sakaguchi, Takuhiro Sonoyama, Genki Ichihashi, Takao Sanaki, Keiko Baba, Yuko Tsuge, Takeki Uehara
medRxiv 2022.06.22.22276792; doi: https://doi.org/10.1101/2022.06.22.22276792
Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study
Hiroshi Mukae, Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Hiroki Sakaguchi, Takuhiro Sonoyama, Genki Ichihashi, Takao Sanaki, Keiko Baba, Yuko Tsuge, Takeki Uehara
medRxiv 2022.06.22.22276792; doi: https://doi.org/10.1101/2022.06.22.22276792
Subject Area
Subject Areas
- Addiction Medicine (351)
- Allergy and Immunology (674)
- Anesthesia (181)
- Cardiovascular Medicine (2667)
- Dermatology (225)
- Emergency Medicine (404)
- Epidemiology (12282)
- Forensic Medicine (10)
- Gastroenterology (766)
- Genetic and Genomic Medicine (4132)
- Geriatric Medicine (387)
- Health Economics (682)
- Health Informatics (2681)
- Health Policy (1008)
- Hematology (365)
- HIV/AIDS (856)
- Medical Education (400)
- Medical Ethics (109)
- Nephrology (443)
- Neurology (3922)
- Nursing (212)
- Nutrition (583)
- Oncology (2057)
- Ophthalmology (592)
- Orthopedics (242)
- Otolaryngology (306)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1122)
- Primary Care Research (458)
- Public and Global Health (6557)
- Radiology and Imaging (1411)
- Respiratory Medicine (874)
- Rheumatology (413)
- Sports Medicine (344)
- Surgery (454)
- Toxicology (54)
- Transplantation (187)
- Urology (167)